(-0.05%) 5 185.16 points
(0.35%) 39 022 points
(-0.22%) 16 297 points
(0.70%) $78.93
(-1.04%) $2.18
(-0.15%) $2 320.80
(0.08%) $27.57
(-0.35%) $984.95
(0.14%) $0.931
(0.09%) $10.91
(0.11%) $0.800
(0.20%) $91.62
-3.37% $ 2.50
Live Chart Being Loaded With Signals
Immuron Limited, a biopharmaceutical company, researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally...
Stats | |
---|---|
Dzisiejszy wolumen | 1 384.00 |
Średni wolumen | 934 780 |
Kapitalizacja rynkowa | 15.24M |
EPS | $0 ( 2023-08-30 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -5.56 |
ATR14 | $0 (0.00%) |
Immuron Limited Korelacja
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Immuron Limited Finanse
Annual | 2023 |
Przychody: | $1.80M |
Zysk brutto: | $1.31M (72.54 %) |
EPS: | $-0.0166 |
FY | 2023 |
Przychody: | $1.80M |
Zysk brutto: | $1.31M (72.54 %) |
EPS: | $-0.0166 |
FY | 2022 |
Przychody: | $765 193 |
Zysk brutto: | $523 502 (68.41 %) |
EPS: | $-0.0114 |
FY | 2021 |
Przychody: | $145 776 |
Zysk brutto: | $94 705.00 (64.97 %) |
EPS: | $-1.516 |
Financial Reports:
No articles found.
Immuron Limited
Immuron Limited, a biopharmaceutical company, researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It markets Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and reduce the symptoms of minor gastro-intestinal disorders, as well as for dietary supplement for digestive tract protection; and Protectyn, an immune supplement to maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III clinical trials to reduce the risk of contracting travelers' diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in clinical development stage focuses on treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and ETEC infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is based in Carlton, Australia.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej